Suraksha Diagnostic Targets 34% EBITDA Floor, Genomics No Major Capex

Suraksha Diagnostic Limited — Q1 FY27 Earnings Call (Quarter ended 30 Jun 2026)

1. Overall Tone of Management: Optimistic

• Management repeatedly emphasizes “very strong start”, “remarkable PAT growth of 40%”, and “continued progress” across financials, clinical capabilities, and strategy.
• Forward-looking language is confident: “we expect”, “we believe”, “we remain focused”, and “we are on track” (e.g., 100 centres by FY28).

2. Key Themes from Management Commentary

• Strong Q1 financial momentum with operating leverage
• Revenue +21% YoY; EBITDA +28% YoY; PAT +40% YoY.
• EBITDA margin expanded to 36% (from 34%), attributed to volume scaling and fixed-cost leverage.
• Network expansion + ramp-up discipline
• Commissioned 1 hub + 3 spokes in Q1; added 2 hubs + 3 spokes in July/Aug.
• Geographic expansion beyond West Bengal: hub in Jharkhand; Tripura hub “will follow shortly.”
• Focus on improving throughput/capacity utilization and maintaining “disciplined execution.”
• Centre profitability improving, including newer centres
• Mature centres EBITDA margin 40.9%.
• Centres <2 years turned profitable: 6.5% EBITDA margin (from -5.5% last quarter).
• Genomics as a growth engine (Suraksha Genomics)
• Genomics revenue Rs. 13.7m, +136% YoY, with five consecutive quarters of sequential growth.
• New Alzheimer blood test and AI-assisted early detection project (with CSIR) highlighted.
• Genomics positioned as a “meaningful pillar” with no major incremental CapEx expected for 2–3 years.
• Margin outlook tied to scaling
• Management links margin expansion to economies of scale and expects minimum ~34% EBITDA for FY27.

3. Q&A Analysis

Theme A: Margin expansion drivers & sustainability

• Core questions
• What explains the ~400 bps margin expansion?
• Can margins reach 33–34% by FY28–29 and are they sustainable across mature and non-mature centres?
• Confidence in achieving 34% EBITDA given mature centres already at 40%+.
• Management response
• Margin expansion: “because of the volume expansion… operating leverage.”
• Sustainability: “Yes, we do” (mature and non-mature).
• FY28–29: “We expect more by the year ’28–’29.”
• FY27: “EBITDA… will not go below 34%” and “minimum of 34% actually for the year.”
• Mature centres growth: cited ~12.5% QoQ and economies of scale.
• Notable / evasive / strong points
• Strong confidence on flooring EBITDA (“will not go below 34%”), but limited discussion of downside risks (e.g., ramp-up dilution, wage inflation, competitive pricing).
• Some answers are high-level (“fixed costs divided amongst larger number of centres”) rather than quantified.

Theme B: Genomics growth trajectory, economics, and CapEx

• Core questions
• Genomics demand outlook (3–4 years), growth trajectory.
• B2B vs B2C mix and whether B2B share will rise.
• Genomics margins and average realizations; market size and revenue potential in 2–3 years.
• How scalable genomics is without incremental CapEx.
• Management response
• Demand: oncology personalization implies “almost all oncology specimens will need genomic study.”
• Competitive edge: Genexus equipment “in final stages of validation”; turnaround reduced to 48 hours vs 14–17 days.
• Mix: currently 80% B2C / 20% B2B, expecting B2B to increase.
• Margins: genomics margins “somewhere around 15% to 20%.”
• CapEx: “no additional major CapEx investment in next 2 to 3 years.”
• Market size: referenced India reaching ~450 million by 2030 (framed as global data-derived).
• Revenue potential: declined to give a precise number; called it “quite subjective.”
• Notable / evasive / strong points
• Average realization question was deflected as “tough” due to wide test price range (from ~Rs. 4,000–5,000 to half a lakh+).
• Market size metric is not clearly defined (revenue vs volume vs market value), reducing interpretability.

Theme C: Centre expansion plan, Capex, and break-even

• Core questions
• Capex outlook and whether on track for 100 centres by FY28.
• How many hubs/spokes to open; centre-level ramp-up and break-even.
• Capex per hub vs spoke; break-even timeline.
• Management response
• Capex: Rs. 70–80 crores for FY27.
• Centres: “on track to open 100 centres by FY ’28.”
• FY27 additions: asked/answered as “6 spokes and 3 hubs” (and later clarified hub/spoke numbers with some inconsistency in phrasing—see Red Flags).
• Hub Capex: ~Rs. 10–10.5 crores; spoke Capex: Rs. 1.5–2 crores.
• Break-even: spoke centre 3–4 months (centre level); HO break-even 8–9 months.
• Notable / evasive / strong points
• Break-even timelines are presented confidently, but without sensitivity to utilization or payer mix.

Theme D: Patient growth quality, repeat rate, and cannibalization

• Core questions
• Why repeat rate declined (from ~52% in FY22–23 to 40%).
• Whether cannibalization impacts mature centres as spokes open.
• Mature cohort like-on-like growth and revenue per test drivers (mix vs pricing).
• Management response
• Repeat rate: decline explained by new patient mix; absolute repeat not “degrowing.”
• Mature growth: mature centres ~12.3% YoY (as stated).
• Revenue per test: attributed to mix change, not price hikes.
• Cannibalization: acknowledged “always impact of cannibalization” but “overall… business does not take a beating.”
• Notable / evasive / strong points
• Repeat-rate explanation is plausible but not backed with cohort-level retention math.

Theme E: B2B/B2C mix, realizations, and pricing discipline

• Core questions
• How they balance B2B volume growth with maintaining realizations/margins.
• Whether B2C discounting occurs; B2B margin challenge.
• Management response
• B2C: “does not have a margin challenge” because they don’t “play that game” of deep discounting.
• B2B: “definitely will have a margin challenge, but then the volume makes up for it.”
• Notable / evasive / strong points
• No quantified B2B realization vs B2C realization spread.

4. Guidance / Outlook

Explicit guidance (quantitative)

• EBITDA margin floor for FY27: “EBITDA… will not go below 34%” (also reiterated as “minimum of 34%”).
• Quarter seasonality commentary (qualitative but tied to margin):
• Q2 expected strong; Q3 muted due to festivities/winter; Q4 strong.
• Capex for FY27: Rs. 70–80 crores.
• Centre expansion:
• “on track to open 100 centres by FY ’28.”
• FY27 planned additions discussed as 3 hubs + 6 spokes (and later clarified again in Q&A; see Red Flags).
• Genomics CapEx: “no additional major CapEx investment in next 2 to 3 years.”

Implicit signals (qualitative)

• Margin expansion mechanism is expected to continue via operating leverage and new centres ramping (centres <2 years “positive trend”).
• Genomics is positioned as a multi-year growth pillar with adoption improving in the medical fraternity.
• Expansion beyond West Bengal is framed as execution-driven rather than demand-constrained.

5. Standout Statements (most revealing)

• Margin confidence (strong): “EBITDA… will not go below 34%” and “minimum of 34% actually for the year.”
• New-centre profitability turning point: centres under 2 years “turned profitable for the first time… 6.5% EBITDA margin from negative 5.5%.”
• Genomics scaling without further heavy CapEx: “no additional major CapEx investment in next 2 to 3 years.”
• Turnaround-time competitive claim: Genexus validation; turnaround “brought down to 48 hours.”
• B2C pricing discipline: “we don’t play that game” (deep discounting) and patients “paying the full price.”
• Repeat-rate rationale: repeat rate down because “new patients numbers are increasing” (absolute repeat not degrowing).

6. Red Flags / Positive Signals

Red Flags

• Hub/spoke plan inconsistency / clarification needed
• Early answer: “6 spokes and 3 hubs.”
• Later Q&A: confusion between “4 hubs and 7 spokes” vs “3 hubs and 7 spokes” and then “4 hubs and 7 spokes” again.
• This creates uncertainty around execution granularity.
• Genomics market size metric unclear
• “450 million by 2030” is stated without clarifying whether it’s revenue, test volume, or market value.
• Average realization for genomics not provided
• Management avoided giving a stable average despite repeated prompts; reliance on wide price dispersion.
• Repeat-rate decline not fully quantified
• Explanation is qualitative; no cohort retention breakdown.

Positive Signals

• Clear evidence of ramp-up improvement
• New centres moved from negative to positive EBITDA margin within a quarter.
• Operational leverage narrative supported by numbers
• Mature centres at 40.9% and overall EBITDA margin expansion.
• Capex discipline
• Hub/spoke Capex ranges provided; genomics CapEx largely already incurred.
• No price hikes / mix-driven revenue
• “We have not increased any prices” (mix change explanation).

7. Historical Comparison & Consistency Analysis (vs prior 3 calls)

a. Change in Tone Over Time

• Current (Q1 FY27): More Optimistic
• “very strong start”, “remarkable PAT growth”, and stronger margin confidence (“will not go below 34%”).
• Prior calls:
• Q2/H1 FY26 (Nov 2025): cautious on margins due to rain/floods and new centre ramp-up; guided FY26 EBITDA margin 33–34%.
• Q3/9M FY26 (Feb 2026): acknowledged pre-operative cost drag; expected margins to revert as centres mature.
• Q4/FY26 (May 2026): strong FY26 performance but still framed margin as impacted by expansion/ramp-up; guided FY27 margin stabilization.
• Shift drivers
• Q1 FY27 shows new centres already profitable and margin floor guidance becomes more assertive.

b. Tracking Past Commitments vs Outcomes

• Commitment: 100 centres by FY28
• Prior (May 2026 call): “touch the 100 centre marked by FY28.”
• Current: “on track to open 100 centres by FY ’28.” ✅ (reaffirmed; no evidence of slippage in current quarter)
• Commitment: FY27 EBITDA margin stabilization around ~33–34%
• Prior (May 2026 call): “FY27… stabilize at around 33%.”
• Current: “will not go below 34%” and “minimum of 34%.” ✅/Improving (slightly better than earlier stabilization target)
• Commitment: Genomics run-rate / scaling
• Feb 2026: genomics run-rate discussed around INR2.1–2.2m/month and incremental growth.
• Current: genomics revenue Rs. 13.7m in the quarter with +136% YoY and sequential growth for five quarters. ✅ (directionally consistent with scaling narrative)

c. Narrative Shifts

• From “margin drag due to ramp-up” → “new centres now profitable”
• Earlier calls emphasized pre-operative cost drag and expected reversion later.
• Now management points to centres <2 years turning profitable and expects margin floor.
• Genomics narrative becomes more operational
• Earlier: genomics as “moat” and lab readiness.
• Now: specific products (Alzheimer blood test), AI project, and equipment validation/turnaround-time claims.

d. Consistency & Credibility Signals

• Medium credibility
• Positives: margin mechanism is consistent (operating leverage + fixed cost absorption), and new-centre profitability improvement is a concrete datapoint.
• Concerns: hub/spoke plan inconsistency and unclear genomics market sizing reduce precision.
• No clear admissions of misses; when asked about growth/volume deceleration, management used measurement caveats (patient tracking) rather than addressing underlying demand drivers.

e. Evolution of Key Themes

• Demand / volumes: improving but with some deceleration in test volume growth pace (Q1 vs prior quarters) acknowledged indirectly.
• Margins: improving trajectory; now framed with a floor rather than a “reversion expectation.”
• Expansion: continues, with increasing emphasis on Jharkhand/Tripura and “Greater Kolkata” penetration.
• Genomics: moved from capability-building to commercial traction + product launches.

f. Additional Insights (Cross-Period Intelligence)

• Risk build-up masked by optimism?
• The call still relies heavily on “economies of scale” and “fixed costs divided,” but Q&A shows management is less willing to quantify genomics economics (average realization, market size definition).
• Defensiveness on metrics:
• Patient/repeat-rate questions previously involved measurement caveats; similar pattern persists (repeat-rate decline explained via new patient mix rather than retention performance).